comprehensive -WSS

comprehensive

author：focus 2025-10-06 19:29:46 Page View：1

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Change Healthcare cyberattack outage could last weeks
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

International team creates first chimeric human

Imageofoneofthechimerichuman-monkeyembryos.SalkInstituteforBiologicalStudiesAteamofscientistsfromthe

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

What causes osteoarthritis? Researchers study link to brain protein

AdobeAkindofproteinimplicatedinAlzheimer’sdiseasemightalsocontributetothebreakdownofcartilagethat’sc

comprehensive

explore

focus

What causes osteoarthritis? Researchers study link to brain protein